Core Viewpoint - Spectral AI, Inc. has announced a 30% increase in its patent portfolio, enhancing its proprietary AI-driven DeepView System for wound assessment, which aims to improve treatment decisions in wound care [4][5]. Patent Portfolio - The total patents granted to the Company increased to 26 as of July 8, 2024, from 20 at December 31, 2023, comprising 12 U.S. patents and 14 international patents [2][4]. - The Company has an additional 38 pending patent applications worldwide, including seven pending U.S. patents and 31 international patents, covering nine distinct patent families [9]. Technology and Applications - The DeepView System utilizes multi-spectral imaging and machine learning to provide objective assessments of wound healing potential, particularly for patients with burns and diabetic foot ulcers [6]. - The technology aims to revolutionize wound care management by offering faster and more accurate treatment insights, ultimately improving patient outcomes and reducing healthcare costs [6]. Future Plans - The Company plans to commence product commercialization initiatives in late 2024, continuing through 2026, leveraging its intellectual property assets as a foundation for success [5].

About Emily Jarvie About the publisher Proactive news team spans the world's key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Proactive has always been a forward looking and enthusiastic technology adopter. Proactive will on o ...

About this content About the publisher Proactive news team spans the world's key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Our human content creators are equipped with many decades of valuable expertise and experience. The ...

Core Viewpoint - Spectral AI, Inc. is addressing potential market manipulation of its stock, particularly through naked short selling, which is believed to negatively impact its share price and that of other de-SPAC transaction companies [1][2]. Company Overview - Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics, specifically aimed at improving treatment decisions in wound care [9]. - The company’s DeepView System is designed to provide clinicians with an objective assessment of a wound's healing potential, thereby enhancing patient outcomes and reducing healthcare costs [9]. Recent Initiatives - Under the leadership of Erich Spangenberg, the company has reached out to Nasdaq and state securities authorities in Florida, Louisiana, and Texas to report potential violations related to naked short selling [7]. - The company has filed letters with the SEC regarding these concerns, with the latest letter dated July 15, 2024, to be made available via Form 8-K [8].

About this content Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup News Service, Gracenot ...

Spectral AI's DeepView™ System is a predictive device that offers clinicians an immediate and objective assessment of a burn wound's healing potential prior to treatment or other medical intervention. The image processing algorithm employed by the DeepView™ System utilizes multispectral imaging that is trained and tested against a proprietary database of more than 340 billion clinically validated data points. The DeepView™ System is non-invasive and cart-based, allowing for exceptional mobility within the h ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

Core Insights - Spectral AI has achieved 100% pediatric patient enrollment at burn centers for its pivotal study aimed at validating the AI-driven algorithm of its DeepView™ System for burn treatment [1][2] - The study is expected to be completed in Q4 2024, leading to a potential FDA approval for the DeepView™ System in 2025 [7] Company Overview - Spectral AI, Inc. is focused on medical diagnostics using AI to enhance treatment decisions in wound care, particularly for burns and diabetic foot ulcers [3] - The DeepView System employs proprietary multispectral imaging and has been trained on over 340 billion clinically validated data points to assess wound conditions [2][3] Technology and Impact - The DeepView System provides immediate, non-invasive assessments of burn injuries, facilitating timely clinical decisions and potentially improving patient outcomes while reducing healthcare costs [3][8] - The system is designed to be used upon a patient's arrival at emergency departments or burn centers, minimizing trauma associated with patient transport [2]

Core Insights - Spectral AI has achieved 100% pediatric patient enrollment at burn centers for its pivotal study on the DeepView™ System, which is designed to validate an AI-driven algorithm for burn treatment [1][2][3] - The pivotal study is expected to be completed in Q4 2024, leading to a potential FDA approval for the DeepView™ System in 2025 [2] - The DeepView™ System utilizes proprietary multispectral imaging and has been trained against a database of over 340 billion clinically validated data points to assess burn wounds accurately [3][4] Company Overview - Spectral AI, Inc. is focused on medical diagnostics, particularly in wound care, with applications for burns and diabetic foot ulcers [4] - The DeepView System aims to provide objective and immediate assessments of wound healing potential, thereby improving patient outcomes and reducing healthcare costs [4]

DALLAS, July 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its inclusion in the Russell Microcap Index following the annual Russell Reconstitution, which took effect after the market close on June 28, 2024. The reconstituted Russell Microcap Index will commence trading on July 1, 2024. Mr. Carlson highlighted ...